CTIS2023-504441-31-00进行中（未招募）1 期
A multicentric phase 1/2 trial to evaluate the safety and efficacy of SOT102 as monotherapy and in combination with standard of care treatment in patients with gastric and pancreatic adenocarcinoma - SN201(CLAUDIO-01)
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 298
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Age =18 years, Part B- Adequate tumor tissue or cytology sample (FFPE blocks) or unstained slides from archival biopsy available or willingness to undergo a fresh tumor biopsy, Part B- Patient has advanced inoperable or metastatic disease, Written informed consent given prior to any trial-specific procedures, Part B- Patient must have at least one measurable lesion according to RECIST 1.1, Part B - Patients with gastric/GEJ adenocarcinoma (gastric B) - Histological or cytological evidence of adenocarcinoma of the stomach or GEJ that is advanced or metastatic, Part B- Patients with gastric/GEJ adenocarcinoma (gastric B) - Must have HER2-negative tumors, Part B- Patients with pancreatic adenocarcinoma (pancreatic B) Histological or cytological evidence of adenocarcinoma of the pancreas that is advanced or metastatic, Part C- Adequate tumor tissue or cytology sample (FFPE blocks) or unstained slides from archival biopsy available or willingness to undergo a fresh tumor biopsy. Tumor sample must have CLDN18.2 expression using a central immunohistochemistry method., Part C- Patient has advanced inoperable or metastatic disease, Part C- Measurable disease according to RECIST 1.1., Patient is, in the judgement of the investigator, an appropriate candidate for experimental therapy, Part C- Patients with gastric/GEJ adenocarcinoma (gastric C) - Must have received at least two prior systemic therapies for advanced or metastatic disease. If HER2 overexpression: must have received anti-HER2 therapy., Part C- Patients with pancreatic adenocarcinoma (pancreatic C) - Histological or cytological evidence of adenocarcinoma of the pancreas that is advanced or metastatic, Adequate organ function as assessed by the following parameters: hematologic; hepatic; renal; prothrombin time/international normalized ratio (INR); albumin; proteinuria; Serum concentrations of potassium, magnesium, and calcium within normal range, Part C- Patients with pancreatic adenocarcinoma (pancreatic C) - Must have received at least one prior systemic therapy for advanced or metastatic disease If HER2 overexpression: must have received anti-HER2 therapy., Part D- Adequate tumor tissue or cytology sample (FFPE blocks) or unstained slides from archival biopsy available or willingness to undergo a fresh tumor biopsy. Tumor sample must have CLDN18.2 expression using a central immunohistochemistry method., Part D- Patient must have at least one measurable lesion according to RECIST 1.1. At least one measurable lesion must be outside of an earlier radiation field or must have progressed after radiation therapy, Part D- Patients with gastric/GEJ adenocarcinoma (gastric D) - Histological or cytological evidence of adenocarcinoma of the stomach or GEJ that is advanced inoperable or metastatic, Part D- Patients with gastric/GEJ adenocarcinoma (gastric D) - Must have HER2-negative tumors, Part D- Patients with pancreatic adenocarcinoma (pancreatic D) - Histological or cytological evidence of adenocarcinoma of the pancreas that is advanced inoperable or metastatic, Eastern Cooperative Oncology Group (ECOG) performance status =1, Patient agrees not to participate in other interventional clinical trials while enrolled in the present trial (with the exception of survival follow-up period), Estimated life expectancy =3 months as per investigator’s assessment, A female patient is eligible to participate if she is not pregnant, not breastfeeding, and one of the following conditions applies: Not a
排除标准
- •Patients with hepatitis B will be eligible if: •there is serologic evidence of a resolved prior HBV infection (HBsAg-negative and anti-HBc–positive, Major surgical intervention =28 days prior to ICF signature or incomplete wound healing after surgical intervention, Patient has received radiation therapy =14 days before day 1 of cycle 1 or has not recovered to grade =1 from treatment-related side effects, Hypersensitivity or intolerance to any component of trial intervention, Time since last transfusion of RBCs =14 days before cycle 1 day 1, Exclusion criteria specific to Part A Part C - Any prior systemic therapy for metastatic cancer other than gastric or pancreatic cancer., Exclusion criteria specific to Part B -General -Patients must not have received any systemic therapy for metastatic disease. Patients must not have received any prior systemic therapy for metastatic cancer other than gastric or pancreatic cancer. Patients with contraindications to any component of the first-line SoC treatment Patients with clinically active inflammatory bowel disease, Exclusion criteria specific to Part B - Patients with pancreatic adenocarcinoma (pancreatic B) Patients more clinically suitable (e.g., with BRCA1/2 mutation) to receive treatment with leucovorin calcium, fluorouracil, irinotecan hydrochloride, and oxaliplatin (FOLFIRINOX) as compared to nab-paclitaxel and gemcitabine according to the investigator’s opinion, Exclusion criteria specific to Part D- General - Patients must not have received any systemic therapy for metastatic disease. Patients must not have received any prior systemic therapy for metastatic cancer other than gastric or pancreatic cancer. Patients with contraindications to any component of the first-line SoC treatment Patients with clinically active inflammatory bowel disease, Exclusion criteria specific to Part D- Patients with pancreatic adenocarcinoma (pancreatic D) Patients more clinically suitable (e.g., with BRCA1/2 mutation) to receive treatment with FOLFIRINOX as compared to nab-paclitaxel and gemcitabine according to the investigator’s opinion, Patient has been previously treated with the maximum cumulative dose of anthracyclines, Patients with hepatitis C will be eligible if: •they have completed curative antiviral treatment and have HCV viral load below the limit of quantification, Severe preexisting medical conditions as per judgement of the investigator, History of interstitial pneumonitis or pulmonary fibrosis, Symptomatic central nervous system malignancy. Patients with asymptomatic or treated central nervous system metastases may be eligible if they are not treated with corticosteroids or anticonvulsants and the disease is stable for at least 60 days., Patient has peripheral sensory neuropathy grade =2, Active infection requiring systemic therapy that is not clinically controlled before the signature of the ICF, Patients with HIV will be eligible if •CD4+ T-cell (CD4+) counts =350 cells/uL •they have no history of AIDS-defining opportunistic infections •they are not currently on HIV therapy, Alcohol or drug abuse as determined by the investigator, Psychiatric condition or social situation that, in the opinion of the investigator, preclude that the patient is able to comply with trial requirements, New York Heart Association class =2 heart failure, unstable angina, coronary angioplasty, coronary stenting, coronary artery bypass graft, myocardial infarction, cerebrovascular accident
研究者
相似试验
进行中（未招募）
1 期
A study to evaluate the safety and efficacy of SOT102 as a single drug or in combination with standard of care treatment, in patients with stomach and pancreas cancerGastric and pancreatic adenocarcinomaMedDRA version: 21.1Level: LLTClassification code 10066354Term: Adenocarcinoma of the gastroesophageal junctionSystem Organ Class: 100000004864MedDRA version: 21.1Level: LLTClassification code 10051971Term: Pancreatic adenocarcinomaSystem Organ Class: 100000004864EUCTR2021-005873-25-ESSOTIO Biotech a.s.269
进行中（未招募）
1 期
A study to evaluate the safety and efficacy of SOT102 as a single drug or in combination with standard of care treatment, in patients with stomach and pancreas cancerGastric and pancreatic adenocarcinomaMedDRA version: 21.1Level: LLTClassification code 10066354Term: Adenocarcinoma of the gastroesophageal junctionSystem Organ Class: 100000004864MedDRA version: 21.1Level: LLTClassification code 10051971Term: Pancreatic adenocarcinomaSystem Organ Class: 100000004864EUCTR2021-005873-25-BESOTIO Biotech a.s.269
进行中（未招募）
不适用
A Trial to assess the safety and efficacy of the medication Eltrombopag, indicated for patients with chronic lymphocytic leukemia along with low platelet counts who are planned to recieve a chemotherapy.EUCTR2010-023022-20-ATniversitätsklinikum Ulm82
进行中（未招募）
不适用
A Trial to assess the safety and efficacy of the medication Eltrombopag, indicated for patients with chronic lymphocytic leukemia along with low platelet counts who are planned to recieve a chemotherapy.CLL patients with thrombocytopenia and indication for chemotherapeutic treatment with alkylating agents and/or purine analoguesMedDRA version: 15.1Level: LLTClassification code 10008977Term: Chronic lymphocytic leukemia recurrentSystem Organ Class: 100000004864MedDRA version: 15.1Level: LLTClassification code 10068919Term: B-cell chronic lymphocytic leukemiaSystem Organ Class: 100000004864EUCTR2010-023022-20-DEniversitätsklinikum Ulm82
进行中（未招募）
不适用
A phase I/II multicentre study to evaluate the safety and efficacy of rituximab (monoclonal antibody anti-CD20) for prevention and/or therapy of EBV-disease. - NDOT AVAILABLEMedDRA version: 9.1Level: LLTClassification code 10015108Term: Epstein-Barr virus infectionEUCTR2007-000468-26-ITOSPEDALE POLICLINICO S. MATTEO